Oxford – September 18, 2026 -- Brainomix, an Oxford-based AI-powered medical imaging company, has been selected to join Future Fifty, the UK's invitation-only scale-up programme run by Tech Nation and Founders Forum Group.
Brainomix joins 24 other companies in a cohort that has raised £1.47 billion collectively
The latest Future Fifty cohort spans 10 sectors including AI, healthtech, biotech, fintech, energy and advanced manufacturing, and employs more than 3,800 people across the group. The programme has previously supported 30% of all UK tech unicorns and 40% of the country's decacorns, including Revolut and Wise.
Brainomix has raised £49 million and secured over 30 regulatory clearances
The company has secured £49 million in private and public funding and obtained more than 30 FDA, CE and other major regulatory clearances across its technology portfolio. Its operations now span more than 20 countries, with its Brainomix 360 Stroke and e-Lung platforms deployed across healthcare systems globally.
CEO Michalis Papadakis says the selection recognizes the company's international scaling efforts
Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said the Future Fifty selection is a recognition of what the company's team has built as it works to help more patients receive the right treatment at the right time through AI-powered imaging.
Carolyn Dawson OBE, CEO of Founders Forum Group, said the programme backs founders in critical sectors with the connections, insights and global exposure needed to scale internationally while keeping the UK competitive on the world stage.
Brainomix plans further platform development and international market expansion
The company is investing in further development of its imaging platforms, expanding its presence in key international markets, and building partnerships across healthcare and life sciences as it enters its next growth phase.